Intellia Therapeutics Inc
NASDAQ:NTLA
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
13.12
32.8
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NTLA stock under the Base Case scenario is 7.61 USD. Compared to the current market price of 14.3 USD, Intellia Therapeutics Inc is Overvalued by 47%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Intellia Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for NTLA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Intellia Therapeutics Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Intellia Therapeutics Inc
Balance Sheet Decomposition
Intellia Therapeutics Inc
Current Assets | 757.2m |
Cash & Short-Term Investments | 691.1m |
Receivables | 12.3m |
Other Current Assets | 53.8m |
Non-Current Assets | 434.3m |
Long-Term Investments | 248.8m |
PP&E | 135.7m |
Other Non-Current Assets | 49.8m |
Current Liabilities | 105.1m |
Accounts Payable | 18.8m |
Accrued Liabilities | 64.1m |
Other Current Liabilities | 22.2m |
Non-Current Liabilities | 115.4m |
Other Non-Current Liabilities | 115.4m |
Earnings Waterfall
Intellia Therapeutics Inc
Revenue
|
81.3m
USD
|
Operating Expenses
|
-994.4m
USD
|
Operating Income
|
-913.1m
USD
|
Other Expenses
|
41.8m
USD
|
Net Income
|
-871.3m
USD
|
Free Cash Flow Analysis
Intellia Therapeutics Inc
USD | |
Free Cash Flow | USD |
NTLA Profitability Score
Profitability Due Diligence
Intellia Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Intellia Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
NTLA Solvency Score
Solvency Due Diligence
Intellia Therapeutics Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Intellia Therapeutics Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NTLA Price Targets Summary
Intellia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for NTLA is 60.18 USD with a low forecast of 14.14 USD and a high forecast of 134.4 USD.
Dividends
Current shareholder yield for NTLA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
NTLA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 485 full-time employees. The company went IPO on 2016-05-06. The firm is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). The company is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). The firm is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned T cell receptor (TCR)-T cell candidate, NTLA-5001 for the treatment of acute myeloid leukemia (AML) and hematopoietic stem cells (HSCs) for the treatment of sickle cell disease.
Contact
IPO
Employees
Officers
The intrinsic value of one NTLA stock under the Base Case scenario is 7.61 USD.
Compared to the current market price of 14.3 USD, Intellia Therapeutics Inc is Overvalued by 47%.